

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Bloomage BioTechnology Corporation Limited**

**華熙生物科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 00963)**

### **APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER**

This announcement is made pursuant to Rule 2.1 of the Code on Takeovers and Mergers (the “**Takeovers Code**”).

Reference is made to the joint announcement issued by Bloomage BioTechnology Corporation Limited (the “**Company**”) and Grand Full Development Limited (the “**Offeror**”) dated 19 June 2017 (the “**Joint Announcement**”) in relation to, among other things, the Offeror’s request to the Board to put forward to the Scheme Shareholders the proposed privatization of the Company by way of a scheme of arrangement under Section 86 of the Companies Law.

Capitalised terms used in this announcement shall have the same meanings as those defined in the Joint Announcement unless otherwise stated.

### **APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER**

The Board is pleased to announce that Gram Capital Limited has been appointed as the independent financial adviser (the “**Independent Financial Adviser**”) to advise the Independent Board Committee in relation to the Proposal, the Scheme and the Option Offer.

Gram Capital Limited is a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activity under the SFO.

The appointment of the Independent Financial Adviser has been approved by the Independent Board Committee in accordance with Rule 2.1 of the Takeovers Code. The letter of advice from the Independent Financial Adviser in respect of the Proposal, the Scheme and the Option Offer will be included in the Scheme Document.

**Shareholders, Optionholders and potential investors should exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their licensed securities dealers or registered institutions in securities, bank manager, solicitor or other professional advisers.**

By Order of the Board  
**Bloomage BioTechnology Corporation Limited**  
華熙生物科技有限公司  
**Gong Anmin**  
*Director*

Hong Kong, 23 June 2017

*As at the date of this announcement, the Directors are:*

*Executive Directors:*

*Ms. Zhao Yan*

*Mr. Jin Xuekun*

*Mr. Gong Anmin*

*Ms. Wang Aihua*

*Non-executive Director:*

*Mr. Yau Wai Yan*

*Independent non-executive Directors:*

*Ms. Zhan Lili*

*Mr. Li Junhong*

*Mr. Xue Zhaofeng*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.*